Indusatumab vedotin
Based on 1 Customer Validation
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 96.37%
- CAS 番号: 1514889-12-3
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Guanylate cyclase (GCC)[1]
Indusatumab vedotin (0.4-25 μg/mL; 72 h) causes antiproliferative effects in pancreatic cancer cell lines[1].
Indusatumab vedotin (12.5 μg/mL; 24 h) arrests cell cycle at G2/M in MIA PaCa-2 and PANC-1 cells, and causes the P-Hitone H3 production[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MIA PaCa-2 and PANC-1 cells
-
Concentration:12.5 μg/mL
-
Incubation Time:24 hours
-
Result:Increased the protein level of P-Hitone H3, indicating tubulin polymerization.
-
Cell Line:MIA PaCa-2 and PANC-1 cells
-
Concentration:12.5 μg/mL
-
Incubation Time:24 hours
-
Result:Decreased cell number in G1 phase and caused an induction of a G2/M arrest.
-
Cell Line:GCC Knock cells and Pancreatic cancer cell lines: L3.6, MIA PaCa-2, Panc 03.27, Panc 05.04 and Panc 02.03
-
Concentration:0.4 μg/mL, 0.8 μg/mL, 1.6 μg/mL, 3.1 μg/mL, 6.3 μg/mL, 12.5 μg/mL, and 25 μg/mL
-
Incubation Time:72 hours
-
Result:Inhibited the cell viability of pancreatic cancer cells, but not GCC Knock cells.
Indusatumab vedotin shows strongly correlated biological activity with exposure in mice bearing one of six different xenograft models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pancreas Explant Xenograft Model in Mouse[1]
-
Dosage:10 mg/kg
-
Administration:Intravenous injection in tail; once weekly for 17-50 days
-
Result:Inhibited the volume growth of 10 types tumors significantly.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1514889-12-3
-
性状 Liquid
-
Color Colorless to light yellow
-
SMILES
[Indusatumab vedotin]
-
別名
MLN0264; TAK-264
-
輸送条件
Shipping with dry ice.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Indusatumab vedotin 関連分類
HY-P99662 関連分類
Powered by Bioz